The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...

AbbVie’s ABBV stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

Cosmetic Surgery Industry The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and collaboration< ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

Baby boomers and users of weight loss drugs suffering from “facial sagging” are flocking to injectable aesthetic treatments ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

Some prominent healthcare and consumer stocks have fallen out of favor with the market, so now is the time to pounce on some great deals.

The National Medical Commission (NMC) is yet to receive the intimation from the Department of Pharmaceutical (DoP) asking it ...

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...

also lead to wrinkles. If you love the lines you’ve earned on your face, we salute you. But if you don’t, and you’ve considered using Botox or fillers, you’re probably wondering how to kick off your ...